This study will obtain preliminary information about whether, and at what dose, cannabidiol
(CBD) may help with insomnia in people living with human immunodeficiency virus (HIV). The
study will be a 5-week randomized, double-blind placebo-controlled phase II trial using daily
oral CBD doses between 50mg and 600mg. Sleep problems will be measured using a wrist-worn
device and by self-report. Performance on tests of thinking skills will be compared before
and after CBD/placebo treatment. Positive study results will provide support for the use of
CBD as a potential treatment for insomnia.